Ditchcarbon
  • Contact
  1. Organizations
  2. Freenome Holdings, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 2 months ago

Freenome Holdings, Inc. Sustainability Profile

Company website

Freenome Holdings, Inc., a pioneering force in the biotechnology sector, is headquartered in the United States. Founded in 2014, the company has rapidly established itself as a leader in the development of advanced multi-omics technology for early cancer detection. Freenome's innovative approach combines artificial intelligence with blood-based biomarker analysis, offering unique insights that enhance diagnostic accuracy. With a focus on colorectal cancer screening, Freenome's flagship product stands out for its ability to detect cancer at its earliest stages, significantly improving patient outcomes. The company has achieved notable milestones, including partnerships with leading healthcare institutions and recognition for its contributions to cancer diagnostics. As a key player in the oncology landscape, Freenome continues to drive advancements that redefine cancer detection and management.

DitchCarbon Score

How does Freenome Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Freenome Holdings, Inc.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.

31%

Let us know if this data was useful to you

Freenome Holdings, Inc.'s reported carbon emissions

Freenome Holdings, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and commitments suggests that Freenome may still be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, it will be essential for Freenome to establish clear climate commitments and reduction initiatives to align with global standards and expectations.

How Carbon Intensive is Freenome Holdings, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Freenome Holdings, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Freenome Holdings, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Freenome Holdings, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Freenome Holdings, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Freenome Holdings, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Freenome Holdings, Inc.'s Emissions with Industry Peers

Thermo Fisher Scientific

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 3 days ago

F. Hoffmann-La Roche AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

Personalis

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Inivata Limited

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Mainz Biomed N.V.

DE
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Adaptive Biotechnologies

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251114.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
AWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy